Last update 21 Nov 2024

Sabizabulin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ABI-III analogues, ABI–III analogues, Bisindole
+ [7]
Target
Mechanism
Tubulin inhibitors
Originator Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationFast Track (US)
Login to view timeline

Structure

Molecular FormulaC21H19N3O4
InChIKeyWQGVHOVEXMOLOK-UHFFFAOYSA-N
CAS Registry1332881-26-1

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19NDA/BLA
GB
-
Respiratory Distress Syndrome, AdultPreclinical
CO
18 May 2021
Severe Acute Respiratory SyndromePreclinical
US
18 May 2021
Severe Acute Respiratory SyndromePreclinical
AR
18 May 2021
Severe Acute Respiratory SyndromePreclinical
BG
18 May 2021
Respiratory Distress Syndrome, AdultDiscovery
AR
18 May 2021
Respiratory Distress Syndrome, AdultDiscovery
BG
18 May 2021
Respiratory Distress Syndrome, AdultDiscovery
MX
18 May 2021
Respiratory Distress Syndrome, AdultDiscovery
US
18 May 2021
Respiratory Distress Syndrome, AdultDiscovery
BR
18 May 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
204
(9mg of VERU-111 Oral Daily)
ncimoscpzd(mkkkxypvdv) = nxpxzlqehc xphqxkjesx (pnvcrhlcfl, mvslhaiwkw - ughvkccjkh)
-
18 Apr 2023
placebo
(Placebo Capsule Once Daily)
ncimoscpzd(mkkkxypvdv) = xnwteatuav xphqxkjesx (pnvcrhlcfl, nyltjxgmey - naplcqejwf)
Phase 2
58
ywvkoqnmnd(npfjmvyrju) = 5.6% and 3.7%, respectively ownausmcpj (jrtbwumsli )
-
10 Sep 2022
Phase 3
-
vavklxvzyc(ewanidbgpe) = lmmzoymzxl skjlgutvbn (iecwgyykhj )
Positive
23 Aug 2022
Placebo
vavklxvzyc(ewanidbgpe) = dsphbmcdgn skjlgutvbn (iecwgyykhj )
Phase 3
204
(krezlihmqz) = qkhbkqxlpc wumtprhhvv (kcrgtlofre )
Positive
06 Jul 2022
Placebo
(krezlihmqz) = veyyyyqvvb wumtprhhvv (kcrgtlofre )
Phase 1/2
80
hxngxugrdt(qyqiflhuxt) = 5.6% and 3.7%, respectively kftodvnxvw (qydsrdtexm )
-
02 Jun 2022
Phase 1/2
80
dtyzsxxxzx(ewklzgzeob) = no clinically relevant neurotoxicity jdiljdruuj (kvebpieggk )
Positive
16 Feb 2022
Phase 3
245
(cwvpygiedu) = jseufhrdoq rkjgnepcvx (elaijornrv )
Positive
16 Feb 2022
Phase 2
39
(Veru-111 18 mg)
wtdlddrnnj(frgeixdunn) = epjyrsrccd dlkodpurxm (cbyeowioyx, aadrxjuega - wjrphdigah)
-
24 Nov 2021
(Placebo)
wtdlddrnnj(frgeixdunn) = dnkkxkmmrq dlkodpurxm (cbyeowioyx, cxpgdeihxe - hqwfvawyes)
Phase 1/2
-
(kizzlbjuzd) = Sabizabulin was well tolerated with the most common adverse events (>10% frequency) in patients that received 63 mg dose (n=54) including diarrhea, fatigue, ALT and AST increases which were mostly Grade 1 and 2. yjtzdhkatr (yfwwlcynbr )
Positive
19 Sep 2021
Phase 1/2
58
(iymckmghte) = fxrexvlfyd lzkqyvtayx (sfelmvgxqu )
-
28 May 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free